Actinium Pharmaceuticals Appoints Qing Liang, PhD, DABR as Vice President, Head of Radiation Sciences to Further Innovation for its AWE Technology Platform and Growing Pipeline of Antibody Radiation Conjugate Therapies

Author's Avatar
Jan 16, 2019
Article's Main Image

Accomplished Medical Physicist will drive relevant activities related to Antibody Radiation Conjugates for targeted conditioning, therapeutic combinations, and AWE technology platform development

PR Newswire